ClinicalTrials.gg
CompletedNCT02614833Updated Oct 5, 2021

IMP321 (Eftilagimod Alpha) as Adjunctive to a Standard Chemotherapy Paclitaxel Metastatic Breast Carcinoma

A Phase 2 interventional study of IMP321 (eftilagimod alpha) and Placebo in Adenocarcinoma Breast Stage IV, sponsored by Immutep S.A.S.. Completed at 29 sites in 7 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-10-05.

Sponsored by Immutep S.A.S. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
242
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Study summary

The proposed Phase IIb clinical study aims to investigate the safety and efficacy of the active immunotherapy IMP321 in combination (adjunctive) with paclitaxel chemotherapy in patients with hormone receptor-positive metastatic breast cancer.

Read the detailed description

This is a multicentre, placebo-controlled, double-blind, 1:1 randomised Phase IIb study in female hormone receptor-positive metastatic breast cancer patients. The study comprises of two stages.

Stage 1 is the open-label, safety run-in stage consisting of cohort 1 and 2 to confirm the (RPTD) of IMP321 in combination with paclitaxel.

Stage 2 is placebo-controlled, double-blind randomisation stage, paclitaxel + IMP321 at the RPTD will be compared to paclitaxel + placebo.

02

Conditions studied

  • Adenocarcinoma Breast Stage IV

Keywords

  • Hormone receptor positive
03

In context

Lead sponsor

Immutep S.A.S. is the lead sponsor of 11 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Able to give written and to comply with the protocol
  2. oestrogen receptor positive and/or progesterone receptor positive breast adenocarcinoma, proven by of the primary tumour and/or metastasis
  3. Female of age 18 years or above
  4. Patients who are indicated to received chemotherapy with weekly paclitaxel
  5. Evidence of as defined by Response Evaluation Criteria version 1.1

6 Laboratory criteria: haematology and biochemistry results within the limits normally expected for the patient population.

Exclusion criteria

Exclusion Criteria:

  1. Prior chemotherapy for breast adenocarcinoma
  2. Disease-free interval of less than twelve months from the last dose of chemotherapy
  3. Inflammatory carcinoma
  4. Candidate for treatment with trastuzumab (or other Her2/neu targeted agents)
  5. Systemic chemotherapy, radiation therapy or any other agent within 4 weeks, endocrine therapy within 1 week prior to first dose of study treatment or CDK4/6 inhibitors within 5 times half-life (acc.to SPC) prior to first dose of study treatment and until completion of study treatment
  6. Symptomatic known cerebral and/or
  7. Serious intercurrent infection
  8. Evidence of severe or uncontrolled cardiac disease ( III-IV) within 6 months prior to first dose of study treatment
  9. Active acute or chronic infection
  10. Active disease requiring therapy
  11. Previous within the last three years other than breast carcinoma
  12. Patients with prior organ or stem cell transplantation
  13. Any condition requiring continuous systemic treatment with either or other immunosuppressive medications within 4 weeks prior to first dose of study treatment.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
242 participants (actual)

Study arms

  • Experimental
    Paclitaxel + IMP321 at the RPTD

    The chemo-immunotherapy phase consists of 6 cycles of 4 weeks. Patient will receive weekly paclitaxel at Days 1, 8 and 15 with adjunctive treatment of study agent, either IMP321, on Days 2 and 16 of each 4-week cycle. After completion of the 6-cycle chemo-immunotherapy phase, responding or stable patients will receive study agent (IMP321) every 4 weeks during the maintenance phase for an additional period of up to 12 injections

    Biological: IMP321 (eftilagimod alpha) · Drug: Paclitaxel

  • Active comparator
    Comparator: Paclitaxel + Placebo

    The chemo-immunotherapy phase consists of 6 cycles of 4 weeks. Patient will receive weekly paclitaxel at Days 1, 8 and 15 with adjunctive treatment of study agent, placebo, on Days 2 and 16 of each 4-week cycle. After completion of the 6-cycle chemo-immunotherapy phase, responding or stable patients will receive study agent (placebo) every 4 weeks during the maintenance phase for an additional period of up to 12 injections

    Drug: Placebo · Drug: Paclitaxel

Interventions

  • In the placebo-controlled, double-blind randomisation stage, paclitaxel + IMP321 at the RPTD will be compared to paclitaxel + placebo

  • DrugPlacebo

    In the placebo-controlled, double-blind randomisation stage, paclitaxel + placebo will be compared to paclitaxel + IMP321 at the RPTD

  • Paclitaxel will be given in both treatment arms (classified as Non IMP)

06

What researchers measure

Primary outcomes

  1. Stage 1 to determine the recommended phase two dose for the randomised phase

    Time frame: Up to 12 months

  2. Assessment of Progression-Free Survival (PFS)

    Time frame: Up to 37 month

Secondary outcomes

  1. Assessment of the safety and tolerability of IMP321 as compared to placebo

    Time frame: Up to 19 months

  2. Assessment of the overall survival (OS)

    Time frame: Up to 48 month

  3. Stage 1: Evaluation of the pharmacokinetic e.g. Peak Plasma Concentration [Cmax]

    Time frame: Up to 12 months

  4. Assessment of the change in quality of life (QOL)

    Time frame: Up to 37 months

  5. Evaluation of the time to next treatment

    Time frame: Up to 37 months

  6. Evaluation of objective response rate (ORR)

    Time frame: Up to 37 months

  7. Evaluation of stable disease

    Time frame: Up to 37 months

Other outcomes

  1. Stage 1: assessment of Immuno-monitoring in a defined subset of 60 patients during the randomised stage

    Time frame: Up to 37 months

07

Study locations

29 sites
  • AZ Sint-Jan Burgge-Oostende
    Brugge, 8000, Belgium
  • Cliniques universitaires Saint-Luc - Institut Roi Albert II - Cancérologie et Hématologie Oncologie clinique
    Brussel, 1200, Belgium
  • AZ Sint-Maarten
    Duffel, 2570, Belgium
  • Universitair Ziekenhuis Antwerpen Breast and Gynecological Oncology Unit
    Edegem, 2650, Belgium
  • UZ Leuven, campus Gasthuisberg Department of General Medical Oncology and Multidisciplinary Breast Centre
    Leuven, 3000, Belgium
  • Clinique Sainte-Elisabeth
    Namur, 5000, Belgium
  • AZ Nikolass
    Sint-Niklaas, 9100, Belgium
  • GZA Ziekenhuizen campus Sint-Augustinus Oncologische Research
    Wilrijk, 2610, Belgium
  • Institut de Cancérologie de la Loire
    Saint Priest en Jarez, 42271, France
  • Institut Curie / Centre René Huguenin
    Saint-Cloud, 92210, France
  • Institut Claudius Regaud - IUC Toulouse - Oncopôle
    Toulouse Cedex 9, 31059, France
  • KEM- Brustzentrum der Kliniken Essen-Mitte
    Essen, 45136, Germany
  • Onkologische Gemeinschaftspraxis am Bethanien-Krankenhaus Centrum für Hämatologie und Onkologie
    Frankfurt, 60389, Germany
  • NCT - Nationales Centrum für Tumorerkrankungen
    Heidelberg, 69120, Germany
  • UFKT - Universitäts-Frauenklinik Tübingen
    Tübingen, 72076, Germany
  • UFU - Universitätsfrauenklinik Ulm
    Ulm, 89081, Germany
  • Szent Margit Kórház Onkológiai Osztály
    Budapest, 1032, Hungary
  • MH Egészségügyi Központ Onkológiai Osztály
    Budapest, 1062, Hungary
  • VU University Medical Center
    Amsterdam, 1081, Netherlands
  • Zuyderland MC
    Geleen, 6162, Netherlands
  • UMCG Medisch Centrum Groningen
    Groningen, 9700, Netherlands
  • HMC Antoniushove
    Leidschendam, 2262 BA, Netherlands
  • MUMC Medical Oncology department
    Maastricht, 6202, Netherlands
  • Erasmus MC
    Rotterdam, 3075, Netherlands
  • VieCuri Medisch Centrum
    Venlo, 5912 BL, Netherlands
  • Kierownik Oddziału Onkologii i Radioterapii Szpital Morski im. PCK w Gdyni
    Gdynia, 81 - 519, Poland
  • St James' Institute of Oncology
    Leeds, West Yorkshire LS9 7TF, United Kingdom
  • The Christie NHS Foundation Trust The Christie Clinic - Medical Oncology
    Manchester, M20 4BX, United Kingdom
  • Nottingham University Hospitals NHS Trust
    Nottingham, NG5 1PB, United Kingdom
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2015, a primary completion of Mar 2020 and a completion of May 2021. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 5, 2015
First posted
Nov 25, 2015
Start
Dec 2015
Primary completionActual
Mar 2020
CompletionActual
May 2021
Last update
Oct 5, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 5, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02614833
Lead sponsor
Immutep S.A.S.
Responsible party
Sponsor
First posted
Nov 25, 2015
Start date
Dec 2015
Primary completion
Mar 2020
Completion
May 2021
Last update
Oct 5, 2021

Study contacts

Immutep S.A.S
study director · Immutep S.A.S.

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Etilagimod alpha

Start the discussion